Note: Single-source report; awaiting corroboration.
President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to implement most-favored-nation (MFN) pricing, aligning U.S. drug prices with the lowest prices paid by other developed countries. This brings the total number of MFN agreements to 26, covering 89% of the branded drug market. The nine companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
The agreements target price reductions for medications treating a broad range of chronic, rare, and costly conditions, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions, and various cancers. All State Medicaid programs will gain access to these MFN prices for drugs from the nine companies, potentially generating billions in savings and strengthening Medicaid for vulnerable populations.
In addition to pricing commitments, the pharmaceutical manufacturers pledged at least $19.6 billion in combined investments in U.S. drug manufacturing. Several companies also agreed to contribute active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign sources and enhance national emergency preparedness. Contributions include levetiracetam by UCB, clindamycin and doxycycline by Sun Pharma, metronidazole and amlodipine by Teva Pharmaceuticals, and tacrolimus by Astellas Pharma.
These actions are part of President Trump’s ongoing efforts to lower drug costs for Americans and improve the resilience of the U.S. pharmaceutical supply chain.